Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cymarin is a cardiac glycoside belonging to the class of cardenolide glycosides and derivatives. It is found in plants such as *Apocynum cannabinum* and *Apocynum venetum*. Cymarin acts by inhibiting the Na+/K+-ATPase pump, leading to increased intracellular calcium concentration, which enhances myocardial contractility (positive inotropic effect) and slows heart rate (negative chronotropic effect). It has been used historically as a cardiotonic agent for conditions like heart failure and arrhythmias. Recent research also suggests potential antitumor activity against breast cancer and pancreatic cancer, as well as antifeedant effects in agriculture[2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cymarin.